Next, we investigated whether these ISG-15+CD8+ T-cell signatures identified through scRNA-seq analyses could serve as predictors of treatment response and validating them using bulk RNA-seq data from GC patients who received immunotherapy. Here, CD8A is linked to gastric cancer.